Abstract:Background. Rho-related coiled helix forming protein kinase (Rho-ROCK) and another important fibrogenic factor-PDGF play a critical role in collagen deposition in rat lung tissue. Yifei decoction (YFT), a Chinese herbal decoction, has been used to treat idiopathic pulmonary fibrosis (IPF) in clinical practice and has produced positive outcomes; however, convincing evidence is currently lacking. The present study aimed to investigate the effects of YFT combined with MitoQ in rats with IPF and to explore the underlying mechanism. Methods. Rat IPF model was established by endotracheal injection of 5 mg/kg BleomycinA5 into the specific pathogen-free SD rats. MitoQ (6.5 μmol/kg once daily), YFT (10 ml/kg once daily), and MitoQ + YFT (6.5 μmol/kg + 10 ml/kg once daily) were used to treat the rat model for 4 weeks, respectively. The normal rats without IPF were used as the controls. After 4 weeks of drug treatment, lung histopathology was assessed. Immunohistochemistry was used to detect the expression of fibronectin and collagen IV in lung tissue. The expression of IL-6, IL-1β, TNF-α, GSH-Px, SOD, MDA, and hydroxyproline was determined by enzyme-linked immunosorbent assay. The expressions of TGFβ1, NOX4, PDGFR-β, and ROCK1 were determined using real-time quantitative PCR and Western blot. Results. After 4 weeks of drug treatment, comparison of the MitoQ + YFT group with the IPF group showed that lung injury scores, W/D, lung tissue hydroxyproline, fibronectin, collagen IV content, and IL-6, IL-1β, TNF-α, and MDA levels were significantly lower ( P < 0.05 ), as well as the expression of TGFβ1, NOX4, PDGFR-β, and ROCK1, but the activity of GSH-Px and SOD was higher ( P < 0.05 ). Conclusion. MitoQ combined with YFT can improve lung injury in rats with pulmonary fibrosis by reducing the secretion of proinflammatory cytokines and inhibiting TGFβ1/NOX4 and PDGF/ROCK signaling pathways. It may provide a new method for the treatment of pulmonary fibrosis.

What problem does this paper attempt to address?

This paper aims to explore the inhibitory effect and mechanism of Yifei Decoction (YFT) combined with mitochondrial coenzyme Q (MitoQ) on the transforming growth factor β1/NADPH oxidase 4 (TGFβ1/NOX4) and platelet - derived growth factor/mitogen - activated protein kinase (PDGF/ROCK) signaling pathways in idiopathic pulmonary fibrosis (IPF). ### Research Background Rho - associated coiled - coil - forming protein kinase (Rho - ROCK) and another important fibrotic factor - platelet - derived growth factor (PDGF) play a crucial role in the collagen deposition process in rat lung tissues. Yifei Decoction is a traditional Chinese medicine decoction, which has been used in clinical practice to treat idiopathic pulmonary fibrosis and has achieved positive results; however, there is currently a lack of convincing evidence. Therefore, this study aims to explore the effect and potential mechanism of Yifei Decoction combined with MitoQ in the rat model of IPF. ### Research Methods - **Animal Model**: Establish an IPF rat model by tracheal injection of bleomycin A5. - **Drug Treatment**: Treat rats with MitoQ (6.5 μmol/kg, once a day), YFT (10 ml/kg, once a day), and MitoQ + YFT (6.5 μmol/kg + 10 ml/kg, once a day) for 4 weeks respectively. - **Control Group**: Normal rats without IPF induction are used as the control group. - **Detection Methods**: - Pulmonary histopathology evaluation - Immunohistochemical detection of the expression of fibronectin and type IV collagen in lung tissues - Enzyme - linked immunosorbent assay (ELISA) to determine the expression of IL - 6, IL - 1β, TNF - α, GSH - Px, SOD, MDA and hydroxyproline - Real - time quantitative PCR (RT - qPCR) and Western Blot to detect the expression of TGFβ1, NOX4, PDGFR - β and ROCK1 ### Research Results - **Lung Injury Score**: Compared with the IPF group, the lung injury score in the MitoQ + YFT group was significantly reduced (P < 0.05). - **Collagen Content**: The contents of hydroxyproline, fibronectin and type IV collagen in the lung tissues of the MitoQ + YFT group were significantly reduced (P < 0.05). - **Inflammatory Cytokines**: The levels of IL - 6, IL - 1β, TNF - α and MDA in the MitoQ + YFT group were significantly reduced (P < 0.05), while the activities of GSH - Px and SOD were significantly increased (P < 0.05). - **Signaling Pathways**: The expressions of TGFβ1, NOX4, PDGFR - β and ROCK1 in the MitoQ + YFT group were significantly reduced (P < 0.05). ### Conclusion MitoQ combined with Yifei Decoction can improve lung injury in IPF rats by reducing the secretion of pro - inflammatory cytokines and inhibiting the TGFβ1/NOX4 and PDGF/ROCK signaling pathways, which may provide a new method for the treatment of pulmonary fibrosis.

Mechanism of Yifei Decoction Combined with MitoQ on Inhibition of TGFβ1/NOX4 and PDGF/ROCK Signal Pathway in Idiopathic Pulmonary Fibrosis

Qingfei Tongluo Mixture Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis through mTOR-Dependent Autophagy in Rats

Protection of Qingfei Xieding prescription from idiopathic pulmonary fibrosis by regulating renin-angiotensin and ferroptosis in MLE-12 cells

Investigation of the Mechanism of Action of Qingzaojiufei Decoction on Idiopathic Pulmonary Fibrosis Based on Network Pharmacology and Experimental Validation

Integrated RNA-sequencing and network pharmacology approach reveals the protection of Yiqi Huoxue formula against idiopathic pulmonary fibrosis by interfering with core transcription factors

Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis

Integrative analysis of the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction in idiopathic pulmonary fibrosis via evidence-based medicine, bioinformatics, and experimental verification

Tectorigenin Inhibits the in Vitro Proliferation and Enhances Mir-338* Expression of Pulmonary Fibroblasts in Rats with Idiopathic Pulmonary Fibrosis.

Protective Effects of Qing-Re-Huo-Xue Formula on Bleomycin-Induced Pulmonary Fibrosis Through the P53/igfbp3 Pathway

Network pharmacology and molecular docking to explore the pharmacological mechanism of Yifei Tongluo granules in treating idiopathic pulmonary fibrosis: A review

Integrating network pharmacology, experimental validation and molecular docking to reveal the alleviation of Yinhuang granule on idiopathic pulmonary fibrosis

Network pharmacology and experimental verification to decode the action of Qing Fei Hua Xian Decotion against pulmonary fibrosis

Qilongtian ameliorate bleomycin-induced pulmonary fibrosis in mice via inhibiting IL-17 signal pathway

Qingfei xieding prescription ameliorates mitochondrial DNA-initiated inflammation in bleomycin-induced pulmonary fibrosis through activating autophagy

[Protective effect and mechanism of Maiwei Yangfei Decoction on pulmonary fibrosis mice based on Nrf2 regulation of oxidative stress]

Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy

Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats.

Mechanistic Insights into the Treatment of Pulmonary Fibrosis with Bioactive Components from Traditional Chinese Medicine Via Matrix Stiffness-Mediated EMT

[Effect of Peitu Yifei Granules on autophagy mechanism in rats with idiopathic pulmonary fibrosis based on PI3K/Akt/mTOR signaling pathway]

Bufei Decoction Alleviated Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Mice by Anti-Inflammation

ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling